Vaccine

Moderna Announces Positive Phase 1/2 Data from mRNA-1083, the Company’s Combination Vaccine Against Influenza and COVID-19

mRNA-1083 showed strong immunogenicity against influenza and COVID-19, with an acceptable reactogenicity and safety profile, compared to licensed standalone vaccinesCompany…

10 months ago

Shineco to Increase R&D to Explore New High-Tech Medical Product Applications

The Recent Acquisition of a Majority Stake in a Manufacturer of Antibacterial and Antiviral Fabrics Expected to Create Synergies for…

10 months ago

U.S. Centers for Disease Control and Prevention Selects Verily to Support National Wastewater Monitoring

Multi-year collaboration utilizes Verily’s Wastewater program to detect the spread of pathogens, including SARS-CoV-2 and MPXVSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Verily,…

10 months ago

FDA Approves Biogen’s TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA®

TOFIDENCE (BIIB800) becomes the first tocilizumab biosimilar to gain FDA approval in the United StatesFDA approval is based on a…

10 months ago

Moderna Recommends Shareholders Reject Amended “Mini-Tender” Offer by TRC Capital Investment Corporation

CAMBRIDGE, MA / ACCESSWIRE / September 29, 2023 / Moderna, Inc. (NASDAQ:MRNA) has become aware that TRC Capital Investment Corporation…

10 months ago

Dyadic to Present at Industry and Investor Events in October

JUPITER, Fla., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology…

10 months ago

Maravai LifeSciences Hosts 2023 Investor R&D Day

Highlights include the company’s strong foundation for growth, focus on innovation and attractive long-term outlookSAN DIEGO, Sept. 29, 2023 (GLOBE…

10 months ago

Ocugen CSO to Participate in 4th Annual Gene Therapy for Ophthalmic Disorders Conference

MALVERN, Pa., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused…

10 months ago

Vaccinex Announces Pricing of $9.6 Million Public Offering

ROCHESTER, N.Y., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company…

10 months ago

Tonix Pharmaceuticals Announces Pricing of $4.5 Million Public Offering

CHATHAM, N.J., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a biopharmaceutical…

10 months ago